Pharmacokinetics/pharmacodynamics of KSP-1007 in combination with meropenem against carbapenemase-producing gram-negative bacteria in a neutropenic murine thigh infection model
Antimicrobial Agents and Chemotherapy · 01.04.2026 · 70 (4)
DOI: 10.1128/aac.01852-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 01.04.2026. Verfasst von Koji Takemoto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Corporate Regulatory Compliance & Quality Assurance Division, Sumitomo Pharma Co., Ltd., Osaka, Japan. Hauptthemen laut MEDLINE: Meropenem, Anti-Bacterial Agents, Bacterial Proteins, Neutropenia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
KSP-1007 is a novel bicyclic boronate-based broad-spectrum β-lactamase inhibitor that improves meropenem (MEM) efficacy against gram-negative bacteria (GNB) producing serine- and metallo-type carbapenemases. We investigated which pharmacokinetics (PK)/pharmacodynamics (PD) parameters of KSP-1007 correlated with MEM/KSP-1007 efficacy against carbapenemase-producing (CP) Enterobacterales (CPE) and Acinetobacter baumannii (CPAB) in a neutropenic murine thigh infection model. Infected neutropenic mice were subcutaneously treated with MEM every 3 h for 24 h alone or in combination with KSP-1007 administered at 3-, 6-, 12-, or 24-h dosing intervals. The bacterial burden in the thigh was assessed 2 h and 26 h after infection. The percentage of the dosing interval at which the free drug concentration exceeded the threshold concentration (% f T>C T ) was a good predictor of activity against serine- and metallo-CPE and CPAB based on coefficients of determinations (R 2 = 0.5–0.8) and a visual inspection of the plots showing % f T>C T against the change in log 10 CFU/thigh, although the area under the 24-h free drug concentration time-curve yielded similar R 2 values. The required values for % f T>C T at 0.25–4 μg/mL were 20.4%–4.2% (stasis) and 45.1%–14.1% (1-log 10 kill) for serine-CPE and 48.6%–13.3% (stasis) and 97.9%–42.3% (1-log 10 kill) for metallo-CPE. The corresponding values for CPAB at thresholds of 0.5–8 μg/mL were 15.3%–4.3% and 33.9%–8.7%. Frequent dosing of KSP 1007 maximized its potentiation of MEM activity against most of the tested CP-GNB strains. Therefore, the in vivo efficacy of KSP-1007 with MEM against CP-GNB was not dependent on the peak free drug concentration of KSP-1007, making KSP-1007 an optimal partner for MEM, which exhibits time-dependent activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Corporate Regulatory Compliance & Quality Assurance Division, Sumitomo Pharma Co., Ltd., Osaka, Japan.
- Research and Development Division, Sumitomo Pharma Co., Ltd., Osaka, Japan.
- Ōmura Satoshi Memorial Institute, Kitasato University, Tokyo, Japan.
ORCID-Profile: Koji Takemoto
Förderung
- National Institute of Allergy and Infectious Diseases
- Japan Agency for Medical Research and Development
Zitieren
APA
Takemoto, K., Kamada, M., Matsushita, K., Matsui, H., Hidaka, J., & Hanaki, H. (2026). Pharmacokinetics/pharmacodynamics of KSP-1007 in combination with meropenem against carbapenemase-producing gram-negative bacteria in a neutropenic murine thigh infection model. Antimicrobial Agents and Chemotherapy, 70(4). https://doi.org/10.1128/aac.01852-25
Vancouver
Takemoto K, Kamada M, Matsushita K, Matsui H, Hidaka J, Hanaki H. Pharmacokinetics/pharmacodynamics of KSP-1007 in combination with meropenem against carbapenemase-producing gram-negative bacteria in a neutropenic murine thigh infection model. Antimicrobial Agents and Chemotherapy. 2026;70(4). doi:10.1128/aac.01852-25
BibTeX
@article{Takemoto2026,
author = {Takemoto, Koji and Kamada, Mami and Matsushita, Keizo and Matsui, Hidehito and Hidaka, Jun and Hanaki, Hideaki},
title = {Pharmacokinetics/pharmacodynamics of KSP-1007 in combination with meropenem against carbapenemase-producing gram-negative bacteria in a neutropenic murine thigh infection model},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {4},
doi = {10.1128/aac.01852-25}
}
EUVIMED